Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Biotest Pharmaceuticals Corp.
WARNING LETTER
•Biotest Pharmaceuticals Corp.•August 15, 2014

Biotest Pharmaceuticals Corp. – FDA Warning Letter, Aug 15, 2014

Record Details

The FDA conducted an inspection of Biotest Pharmaceuticals Corporation in Boca Raton, Florida, from August 5 to August 15, 2014, revealing significant deviations from current good manufacturing practice (CGMP) requirements in the manufacture of Bivigam, (b)(4)-HB, and Rabies Immune Globulin intermediates. These deviations violate Section 501(a)(2)(B) of the FD&C Act, requirements of the biologics license application, and 21 CFR Part 601. Key violations include the failure to document manufacturing investigations for out-of-specification (OOS) test results, and the failure to validate minimum and maximum process times and mixing times for the Bivigam and (b)(4) HB manufacturing processes. Additionally, the firm failed to validate Method QC 2100 Revision 16 for total protein determination in Rabies Immune Globulin intermediates. A significant deficiency was the failure to inform the FDA about changes in product, production process, quality controls, equipment, facilities, personnel, or labeling, as mandated by 21 CFR 601.12. These issues indicate a failure of the quality control unit to ensure product identity, strength, quality, and purity. FDA requires a comprehensive, global assessment of all manufacturing operations to achieve CGMP compliance. Biotest's initial response was deemed insufficient, lacking details on quality unit oversight. The company must provide a detailed written response within 15 working days outlining specific corrective actions and preventative measures. Failure to promptly correct these deviations may result in severe regulatory actions, including license suspension, revocation, seizure, or injunction.

Company
Biotest Pharmaceuticals Corp.
Inspection date
August 15, 2014
Product type
Biologics
Office
Office of Regulatory Affairs
Person
  • Alonza E. Cruse (Director)
View Company Profile

ID · 47e446ea-5d50-4e96-b5a5-a59add1aae96

Violation Codes2
FD&C Act 501(a)(2)(B)21 CFR 601.12

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Biotest Pharmaceuticals Corp.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.